1. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6–7 months of age: a phase 1/2 randomized trial
- Author
-
Sáez-Llorens, Xavier, primary, Norero, Ximena, additional, Mussi-Pinhata, Marisa Márcia, additional, Luciani, Kathia, additional, Salamanca de la Cueva, Ignacio, additional, Díez-Domingo, Javier, additional, Lopez-Medina, Eduardo, additional, Epalza, Cristina, additional, Brzostek, Jerzy, additional, Szymański, Henryk, additional, Boucher, François D, additional, Cetin, Benhur S, additional, De Leon, Tirza, additional, Cagri Dinleyici, Ener, additional, Marín Gabriel, Miguel Ángel, additional, Ince, Tolga, additional, Macias-Parra, Mercedes, additional, Langley, Joanne M, additional, Martinón-Torres, Federico, additional, Rämet, Mika, additional, Kuchar, Ernest, additional, Pinto, Jorge, additional, Puthanakit, Thanyawee, additional, Baquero-Artigao, Fernando, additional, Castelli Gattinara, Guido, additional, Merino Arribas, Jose Manuel, additional, Ramos Amador, Jose Tomas, additional, Szenborn, Leszek, additional, Tapiero, Bruce, additional, Anderson, Evan J, additional, Campbell, James D, additional, Faust, Saul N, additional, Nikic, Vanja, additional, Zhou, Yingjun, additional, Pu, Wenji, additional, Friel, Damien, additional, Dieussaert, Ilse, additional, Gonzalez Lopez, Antonio, additional, McPhee, Roderick, additional, Stoszek, Sonia K, additional, and Vanhoutte, Nicolas, additional
- Published
- 2023
- Full Text
- View/download PDF